ArticleNature communications2025
Reno-protective CT contrast nanoagent targets proximal tubular epithelium for kidney disease imaging and repair in a mouse model.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Self-Amplified Activatable Fluorescent Probe for Early Diagnosis of Acute Kidney Injury and High-Throughput Screening of Natural Protectants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Contrast-sparing CT using renal-clearable gold nanoclusters for early spatial mapping of renal dysfunction.Science advances · 2026Article
- Iodine-doped carbon dots for fluorescence/computed tomography imaging and photodynamic therapy of tumor cells.RSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
| CT imaging is widely used in clinics for disease diagnosis, but its application in renal function evaluation is limited due to nonspecific distribution and nephrotoxicity of clinical iodinated contrast agents. Herein, we developed an ultrasmall renal-clearable gold nanoparticle-based CT contrast nanoagent (E-Au-Agents) coated with antioxidant L-ergothioneine, enabling reno-targeting and reno-protection for sensitive detection and effective relief of renal dysfunction in female mice. After glomerular filtration, E-Au-Agents specifically recognized OCTN1 transporters on proximal tubular epithelium, followed by clathrin-mediated endocytosis with subsequent tubular reabsorption or re-elimination pathways. This tubular-targeting was markedly enhanced in injured kidneys, allowing rapid CT detection of acute kidney injury, followed by oxidative stress suppression. Remarkably, E-Au-Agents progressively repaired injured kidneys, allowing their eventual clearance through recovered kidneys instead of long-term renal accumulation, a drawback commonly observed in other renal-clearable agents. Collectively, we developed a promising contrast agent for renal CT imaging with dual capabilities of reno-targeting and reno-protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.